Core Insights - Micromem Technologies has developed a liquid-phase nanowire bio-chemical sensor capable of detecting disease biomarkers at ultra-low concentrations, marking a significant advancement in medical diagnostics [1][2]. Technology Development - The sensor achieves a limit-of-detection performance down to 1 picomolar (pM) with a sensitivity of 20mV/decade, allowing for the identification of previously undetectable inflammatory and pathological biomarkers [2]. - The initial target analyte for this sensor is TREM-1, which is associated with various diseases such as atherosclerosis, cancer, colitis, and fibrosis [3]. Market Potential - The global demand for biomarker diagnostics is projected to exceed $100 billion USD by 2030, presenting a substantial opportunity for partnerships with biotech, pharmaceutical, and diagnostics companies [5]. - The sensor platform is derived from work for the Department of National Defence and is evolving into a commercial diagnostic tool [5]. Product Features - The sensor platform offers ultra-low detection thresholds suitable for early-stage disease monitoring and is customizable for other critical biomarkers related to cancer and autoimmune diseases [8]. - It provides high signal clarity with real-time, low-noise output, and is compact and integratable for use in lab-on-a-chip, point-of-care, or remote diagnostic devices [8]. - The manufacturing process utilizes conventional photolithography techniques, ensuring efficient and low-cost production essential for widespread clinical adoption [8]. Strategic Focus - Micromem is seeking co-development and deployment opportunities with strategic industry partners to enhance commercial readiness [7].